The company said total revenues for the 3 months ended September 30, 2026 were $5,513 million, growing 7.2% as reported and 6.2% organically. Sales of services rose 8.1%.

1. 01

   The company said total revenues for the 3 months ended September 30, 2026 were $5,513 million, growing 7.2% as reported and 6.2% organically. Sales of services rose 8.1%.

2. 02

   GE HealthCare said third-quarter operating income was $805 million, up $152 million, and Adjusted EBIT was $913 million (Adjusted EBIT margin of 16.6%). It cited higher sales volume, higher pricing and lower tariff expenses as factors in the gross profit increase.

3. 03

   The company said direct tariffs negatively impacted Operating income by $53 million for the three months and $209 million for the nine months ended 3 and 9 months. It received tariff refunds of $55 million in 3 months and recognized pre-tax benefits from tariff refunds of $9 million related to tariffs incurred in 2025.

4. 04

   The company said operating cash flow for 2026 over the 9 months was $1,365 million, and cash used for investing activities was $2,726 million. Investing activities included $2,293 million in purchases of businesses, net of cash acquired, related to the Intelerad acquisition.

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Structured SEC financial data for this filing is not available yet. Please check the figures in the SEC filing.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.